I-Mab (IMAB) Set to Announce Earnings on Thursday

I-Mab (NASDAQ:IMAB - Get Free Report) is set to post its quarterly earnings results before the market opens on Thursday, November 14th. Analysts expect I-Mab to post earnings of ($0.16) per share for the quarter.

I-Mab (NASDAQ:IMAB - Get Free Report) last posted its quarterly earnings results on Wednesday, August 28th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.44. On average, analysts expect I-Mab to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

I-Mab Trading Down 0.9 %

I-Mab stock traded down $0.01 during mid-day trading on Thursday, reaching $1.08. The company had a trading volume of 387,877 shares, compared to its average volume of 350,549. The stock's 50-day simple moving average is $1.20 and its 200-day simple moving average is $1.44. I-Mab has a 1 year low of $0.99 and a 1 year high of $2.54.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $8.00 target price on shares of I-Mab in a research note on Tuesday, September 17th.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.